Answers are grounded in this paper and cite their sources.
Mesoporous silica nanoparticles are modified with dual targeting ligands, i.e., folic acid and dexamethasone, to construct a cancer-cell-specific nuclear-targeted delivery system. The resulting nanocarriers can not only enhance the inhibition efficacy of doxorubicin on Hela cells through active nucleus accumulation but also reduce toxic side effects on noncancer cells though receptor-mediated selective cellular uptake.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: